Myofibroblastoma (MFB) is an extremely rare benign tumor that can arise in various organs, but commonly in the breast. Albeit it is a benign tumor, the diagnosis is frequently challenging with insurmountable difficulties as it might be erroneously diagnosed as a malignancy. Herein we are reporting a large-sized MFB presented as a non-tender, firm mass which interestingly was adherent to the skin and was initially thought as cancer. The patient underwent a wide local excision and histology confirmed MFB, and had no evidence of recurrence up to 8 months post-operatively.
Introduction: The leftover ureteric stump after a simple nephrectomy is rarely symptomatic. Here, we report a unique case of ureteric stump stones that likely developed de novo and patients became symptomatic.
Case Report: We report the case of a 53-year-old female, who had benign right nephrectomy for a non-functioning kidney 17 years ago and presented with three years history of recurrent urinary tract infections and right-side abdominal pain. A continuous unenhanced computed tomography scan confirmed the presence of multiple de novo stones in the leftover ureteric stump, which was successfully treated by an open transperitoneal ureteric stumpectomy. She was asymptomatic at 12 months post-operative follow-up. We describe problems of leftover ureteric stumps and the possible pathophysiology of the stones formation in this group of patients.
Conclusion: Albeit rare, various symptoms and complications can develop in the leftover stump, including stumpitis, urinary tract infections, and calculi. Therefore, discussion with patients of ureteric stump complications is recommended.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.